FibroGen, Inc. Files Registration Statement For Proposed Initial Public Offering

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., (FibroGen) a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs, announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. All shares in the offering will be sold by FibroGen. The number of shares to be offered and the price range for the offering have not yet been determined.

Help employers find you! Check out all the jobs and post your resume.